Adenosine Receptor May Help 'Turn Off' Pain

Share this content:
A3AR drugs activated an inhibitory transmitter system known as the gamma amino-butyric acid (GABA) system
A3AR drugs activated an inhibitory transmitter system known as the gamma amino-butyric acid (GABA) system

Medications that target the A3 adenosine receptor can "turn off" pain signals in the spinal cord to provide relief from chronic pain, according to a study published in the Journal of Neuroscience

Daniela Salvemini, PhD, of Saint Louis University, and colleagues teamed up with researchers from the National Institutes of Health, the University of Arizona and two institutes in Quebec, Canada, to investigate a new target for treating chronic pain: the A3 adenosine receptor or A3AR.

In earlier studies, Salvemini's laboratory demonstrated that two drugs which target the A3AR -- IB-MECA and MRS5698 -- were effective in treating several models of chronic pain, including painful chemotherapy-induced neuropathy, metastatic cancer pain, and nerve injury. More recently, the group sought to uncover the mechanism of A3AR pain relief.

"Chronic pain can result from the loss of regulatory mechanisms in the nervous system pathway that transmits pain," Salvemini said in a press release. "Adenosine acts as a regulatory signaling molecule in other areas of the nervous system, so we hypothesized that A3AR might also play a role in regulating pain signals during pain processing."

Salvemini and colleagues found that A3AR drugs not only relieved pain, but did so by activating an inhibitory transmitter system known as the gamma amino-butyric acid (GABA) system. In areas of the spinal cord and brain dedicated to pain processing, A3AR activation promoted GABA signaling by preventing the breakdown and removal of GABA from neuronal synapses.

"In chronic pain, GABA signaling is often lost or diminished. Our A3AR drugs were able to restore GABA signaling in areas that process pain and 'turn off' the signals that maintain the pain state," Salvemini said.

With A3AR drugs demonstrating good safety profiles in clinical trials as anti-inflammatory and anti-cancer agents, Salvemini and colleagues noted they are enthusiastic about the potential of these new drugs to treat chronic pain in patients.

Reference

1. Salvemini D. J Neurosci. 2015; 35(15):6057-6067.

You must be a registered member of Clinical Pain Advisor to post a comment.

Sign Up for Free e-Newsletters